Mersana Therapeutics to Host First Quarter 2022 Conference Call on May 9, 2022
Mersana Therapeutics, Inc. (NASDAQ: MRSN) announced it will present business updates and financial results for Q1 2022 on May 9, 2022. A conference call will be held at 8:00 a.m. ET, accessible via phone or live webcast. Mersana focuses on developing antibody-drug conjugates (ADCs) for cancer treatment, including lead candidate upifitamab rilsodotin (UpRi) for ovarian cancer. Key trials include UPLIFT and UPGRADE, along with ongoing development of XMT-1592 and other ADCs.
- None.
- None.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced that it will provide business updates and report financial results for the first quarter ended March 31, 2022 on Monday, May 9, 2022 and will host a conference call and webcast at 8:00 a.m. Eastern Time that morning.
To access the call, please dial 877-303-9226 (domestic) or 409-981-0870 (international) and provide the Conference ID 4289737. A live webcast of the presentation will be available on the Investors & Media section of the Mersana website at www.mersana.com, and a replay of the webcast will be available in the same location following the conference call for at least 90 days thereafter.
About Mersana Therapeutics
Mersana Therapeutics is a clinical-stage biopharmaceutical company using its differentiated and proprietary ADC platforms to rapidly develop novel ADCs with optimal efficacy, safety and tolerability to meaningfully improve the lives of people fighting cancer. Mersana’s lead product candidate, upifitamab rilsodotin (UpRi), is a Dolaflexin ADC targeting NaPi2b and is being studied in UPLIFT, a single-arm registrational trial in patients with platinum-resistant ovarian cancer, as well as in UPGRADE, a Phase 1/2 umbrella trial evaluating UpRi in combination with other ovarian cancer therapies. XMT-1592, Mersana’s second ADC product candidate targeting NaPi2b-expressing tumors, was created using Mersana’s customizable and homogeneous Dolasynthen platform and is in the dose exploration portion of a Phase 1 clinical trial. Mersana’s early-stage programs include XMT-1660, a Dolasynthen ADC targeting B7-H4, as well as XMT-2056, a STING-agonist ADC developed using the Company’s Immunosynthen platform and targeting a novel epitope of human epidermal growth factor receptor 2 (HER2). In addition, multiple partners are using Mersana’s platforms to advance their ADC pipelines. Mersana Therapeutics was recently named among the 2021 Top Places to Work in Massachusetts by The Boston Globe. Mersana routinely posts information that may be useful to investors on the “Investors and Media” section of its website at www.mersana.com.
Contact:
Investor & Media Contact
Jason Fredette
617-498-0020
jason.fredette@mersana.com
FAQ
When will Mersana Therapeutics report its financial results for Q1 2022?
What is the conference call number for Mersana Therapeutics' financial results announcement?
What is the lead product candidate of Mersana Therapeutics?
What trials is Mersana Therapeutics conducting for ovarian cancer?
How can I access the Mersana Therapeutics conference call webcast?
What is Mersana Therapeutics' focus in biopharmaceuticals?
